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OBJECTIVES We studied the efficacy of intracoronary brachytherapy (ICB) after successful coronary
stenting in diabetic patients with de novo lesions.
BACKGROUND Intracoronary brachytherapy has proven effective in preventing recurrences in patients with
in-stent restenosis. However, the role of ICB for the treatment of de novo coronary stenoses
remains controversial.
METHODS Ninety-two patients were randomized to either ICB or no radiation after stenting.
Primary end points were in-stent mean neointimal area (primary end point of efficacy)
and minimal luminal area of the entire vessel segment (primary end point of effective-
ness), as assessed by intravascular ultrasound at six-month follow-up. Quantitative
coronary angiography analysis was performed at the target, injured, irradiated, and entire
vessel segments.
RESULTS At follow-up, the in-stent mean neointimal area was 52% smaller in the ICB group (p 
0.0001). However, there was no difference in the minimal luminal area of the vessel
segment (4.5  2.4 mm2 vs. 4.4  2.1 mm2). Restenosis rates increased progressively by
the analyzed segment in the ICB group: target (7.1% vs. 20.9%, p  0.07), injured (9.5%
vs. 20.9%, p  NS), irradiated (14.3% vs. 20.9%, p  NS), and vessel segment (23.8%
vs. 25.6%, p  NS). At one year, 1 cardiac death, 6 myocardial infarctions (MIs) (3 due
to late stent thrombosis), and 10 target vessel revascularizations (TVRs) (6 due to the
edge effect) occurred in the ICB group, whereas in the nonradiation group, there were 11
TVRs and no deaths or MIs.
CONCLUSIONS Intracoronary brachytherapy significantly inhibited in-stent neointimal hyperplasia after
stenting in diabetic patients. However, clinically this was counteracted by the occurrence of
the edge effect and late stent thrombosis. (J Am Coll Cardiol 2004;44:520–7) © 2004 by
the American College of Cardiology FoundationI
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ciabetes mellitus, a major risk factor for atherosclerosis,
s commonly affecting patients (up to 25%) referred for
ercutaneous or surgical treatment of coronary artery
isease (1,2). In particular, after percutaneous coronary
nterventions, diabetic patients have higher mortality,
estenosis rates, and also disease progression at different
See page 538
ites (3,4), as compared with nondiabetics. Intracoronary
rachytherapy (ICB) has emerged as an effective tech-
ique to prevent recurrences in patients treated for
n-stent restenosis (5–9). Besides, diabetics remain as one
f the subgroups of patients with in-stent restenosis that
enefits most from ICB (10 –12). However, the role of
From the San Carlos University Hospital, Madrid, Spain. This study was awarded
y the 2001 Basic and Clinical Investigation Grant of the Spanish Society of
ardiology and the FIS Grant 2001 01/0539.
Manuscript received August 8, 2003; revised manuscript received February 6, 2004,gccepted February 10, 2004.CB to prevent restenosis after percutaneous coronary
ntervention in de novo coronary lesions remains contro-
ersial (13–16). We sought to investigate whether ICB is
ffective in preventing restenosis after stenting de novo
oronary stenoses in patients with diabetes mellitus.
ETHODS
tudy design. This was a single-center, prospective, ran-
omized, unblinded, controlled trial. The primary objective
f this study was to assess the efficacy of intracoronary
eta-radiation on neointimal proliferation inhibition after
oronary stent implantation in diabetic patients assessed by
ntravascular ultrasound (IVUS) at six-month follow-up.
he trial complied with the provisions of the Declaration of
elsinki regarding investigations involving human subjects
nd was approved by the medical ethics committee of our
nstitution. Written, informed consent was obtained from
ll patients. All events were judged by an independent
ommittee that was unaware of the treatment allocation
roup.
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August 4, 2004:520–7 Intracoronary Brachytherapy in Diabetic Patientsatient selection. Patients were eligible for the study if
hey were identified as non–insulin-dependent or insulin-
ependent diabetics, according to a World Health Organi-
ation report (17). Besides, patients had to be receiving
harmacologic (insulin or hypoglycemic agents) treatment
or at least one month before the procedure. Patients with
igns and/or symptoms of ischemia and de novo significant
oronary stenoses were included. Target lesions had to be
menable for stenting, ICB, and IVUS imaging. The
eference diameter had to be between 2.5 and 4 mm, as
isually assessed, and the lesion length had to be 35 mm.
andomization was performed by a computer-generated
ode after the coronary stenting was considered successful
ccording to angiographic (residual stenosis after stenting
15% of the luminal diameter) and IVUS criteria (complete
pposition of the stent throughout its entire length, minimal
uminal area 80% of reference segment luminal area, and
bsence of complications such edge dissections). There was
sub-randomization according to the type of diabetes
ellitus (insulin- or non–insulin-dependent). Main exclu-
ion criteria included a history of chest radiation, injured
egment 45 mm during percutaneous coronary interven-
ion, myocardial infarction (MI) within the preceding 72 h,
tenoses located in a saphenous vein graft or internal
ammary artery, and use of debulking techniques during
he procedure.
From February 2001 to April 2002, 92 patients were
nrolled in this trial and randomly assigned (46 in each
roup) to receive or not receive beta-radiation after success-
ul stenting. The sample size was calculated for a difference
f 30% in the mean in-stent neointimal hyperplasia (NIH)
rea between the groups (estimated for a mean NIH area of
.2 mm2 in the nonradiation group vs. 1.5 mm2 in the
adiation group), with a standard deviation of 1.5, alpha
rror of 0.05, and beta error of 0.20, as well as 10% missing
alues during follow-up.
rocedural details. All patients were taking aspirin (100
o 250 mg) and received intravenous heparin (100 IU/kg)
efore the procedure. If the duration of the entire
rocedure exceeded 30 min, the activated clotting time
as measured and intravenous heparin was given to
aintain it above 250 s. The percutaneous coronary
Abbreviations and Acronyms
CK  creatine kinase
ICB  intracoronary brachytherapy
IVUS  intravascular ultrasound
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimal luminal diameter
NIH  neointimal hyperplasia
QCA  quantitative coronary angiography
TLR  target lesion revascularization
TVR  target vessel revascularizationntervention was performed according to standard clinical Lractice. Abciximab was administered at the discretion of
he operator. To ensure successful stent implantation,
VUS analysis was performed immediately afterward.
ntracoronary nitrates (0.2 mg nitroglycerin) were sys-
ematically administered before IVUS. A 2.6-F, 40-MHz
VUS catheter (CVIS, Atlantis plus, Boston Scientific,
unnyvale, California) was advanced distal to the treated
ite. A continuous, motorized pullback at a speed of 0.5
m/s was carried out. This was followed by an electro-
ardiographically (ECG)-gated pullback at a step size of
.2 mm. Both pullbacks were performed from the most
istal part of the target vessel that was suitable for placing
he IVUS probe up to the ostium of the artery. After
uccessful stenting, patients were randomized to receive
adiation or not. Radiation was performed by means of
he Guidant Galileo Intravascular Brachytherapy System
Guidant Corporation Vascular Intervention, Houston,
exas), which uses the 27-, 32-, or 52-mm-long center-
ng balloon catheters, with nominal diameters of 2.5, 3.0,
nd 3.5 mm (18). Patients allocated to radiation received
0 Gy at 1 mm beyond the luminal diameter. Prescrip-
ion was based on the average of the luminal diameters at
he proximal and distal reference segments, as assessed by
VUS. Positioning of the centering balloon was per-
ormed after stenting, trying to ensure complete coverage
f the injured segment and a minimum of 5 mm at both
argins to avoid geographic miss (19). For those patients
ot randomized to radiation, no sham source was used,
nd the procedure ended after IVUS imaging. An anti-
latelet regimen included 100 to 250 mg aspirin indefi-
itely and a 300-mg loading dose of clopidogrel, followed
y 75 mg/day for one month in the control group or for
ne year in the radiation group. At six-month angio-
raphic follow-up, further IVUS analysis of the treated
egment was performed.
efinitions. Death was reported as cardiac or noncardiac
eath. Q-wave MI was defined as the development of new,
athologic Q waves in two or more ECG leads, with
ostprocedural creatine kinase (CK) levels of twice the
pper limit of normal (190 U/l) and CK-MB levels above
ormal. Non–Q-wave MI was defined as an elevation of
ostprocedural CK levels of twice the upper limit of normal,
ith CK-MB above normal. Device success was defined as
he attainment of residual stenosis 15% by quantitative
oronary angiography (QCA) and the successful delivery of
he radiation device. Procedural success was defined as
evice success without in-hospital major adverse cardiac
vents (MACE), including death, MI, or emergency coro-
ary artery bypass graft surgery or repeat angioplasty. Target
essel revascularization (TVR) was defined as revasculariza-
ion within the treated vessel, and target lesion revascular-
zation (TLR) as revascularization within the irradiated plus
dge segment on follow-up angiography. All TLR/TVRs
equired a significant stenosis and objective evidence of
schemia related to the restenotic artery before treatment.
ate stent thrombosis was defined as the occurrence of stent
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Intracoronary Brachytherapy in Diabetic Patients August 4, 2004:520–7hrombosis beyond one month-follow-up (20). A geo-
raphic miss was defined as injured coronary segments
eceiving low-dose radiation (19). Two independent ana-
ysts reviewed all cine films to assess the incidence of
eographic miss. A coronary aneurysm was defined as
oronary dilation 1.5 times the reference diameter consid-
red as normal on the follow-up angiogram. Late stent
alapposition was defined as the presence of unapposed
tent struts at follow-up IVUS analysis in the absence of
uch stent malapposition at the index procedure.
VUS analysis. Postprocedural and follow-up IVUS stud-
es were analyzed by an independent core laboratory (Uni-
ersity of Florida Health Science Center, Jacksonville,
lorida), which was blinded to the treatment protocol.
olumetric analysis of the treated segment was performed
rom the three-dimensional reconstruction derived from the
CG-gated image acquisition and digitization (EchoScan,
omtec, Munich, Germany), followed by the automated
ontour detection system for quantitative analysis of the
umen, stent, plaque, and total vessel area and volumes (Fig.
). This method has been extensively validated in vitro and
n vivo (21–23). To define the reference segments to be
nalyzed at the core laboratory (stented and vessel seg-
ents), two strategies were followed: in the ICB group, the
tent was identified in the longitudinal view, and the vessel
egment (irradiated plus edges) was defined by the recog-
ition of angiographic anatomic landmarks noted during
ositioning of the centering catheter in the longitudinal
iew from IVUS. In the control group (no sham source), the
igure 1. Cross-sectional (A and A’) and longitudinal (B and B’) intravas
t follow-up. Luminal, plaque, and total vessel function curves are represe
ntra-stent neointimal hyperplasia is shown.tent was also identified on the longitudinal view, and the tessel segment was defined as that which, when centered on
he stent, included the length of the hypothetically needed
adiation catheter plus 5 mm both edges. This method
ade the entire vessel segments comparable between groups
mean length of vessel segment in the ICB group 37  4
m vs. 36  6 mm in the control group, p  NS). In the
vent of total occlusion at follow-up, it was imputed that the
ntire volume of the stent was completely filled with NIH.
CA analysis. Quantitative coronary angiography was
one with the CMS-GFT system (Medis, Leiden, the
etherlands). Angiographic parameters of restenosis were
nalyzed within the target, injured, irradiated, and total
nalyzed segment to include the edges, according to a
reviously validated methodology (24). A lumen of 0 mm
as imputed if a total occlusion was present at follow-up.
he binary restenosis rate was defined as 50% diameter
arrowing at follow-up within the segment subject to
nalysis. Acute gain was defined as the change in minimal
uminal diameter (MLD) of the analysis segment from
efore to after the procedure. Late loss was defined as the
hange in MLD from the final procedure to the follow-up
ngiogram. Proximal and distal edges were defined as being
mm from the radiated segment.
tudy end points and follow-up. The primary end point
as double: in-stent mean neointimal area at six-month
ollow-up (primary end point of efficacy) and minimal
uminal area of the entire vessel segment (primary end point
f effectiveness). The rationale behind the use of both
VUS-assessed primary end points is first to evaluate the full
ultrasound images of a coronary segment immediately after treatment and
n the bottom charts (C and C’). In this example, a marked increment ofcular
nted iherapeutic effect of brachytherapy under ideal conditions of
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August 4, 2004:520–7 Intracoronary Brachytherapy in Diabetic Patientsrandomized trial (efficacy). Secondly, the impact of the
reatment in the “real world” of everyday clinical practice
effectiveness) is measured in the entire vessel segment,
here both desired and undesired effects (geographic miss,
dge effect, or late thrombosis) may occur. Secondary end
oints included angiographic parameters of restenosis as
ssessed by QCA at six-month follow-up: in-stent late loss
s a secondary end point of efficacy, vessel segment MLD as
secondary end point of effectiveness, and binary restenosis
ate; MACE, including death, MI, and TVR at 30 days and
, 12, and 13 months; and development of complications
uch as aneurysm formation, stent thrombosis, edge effect
geographic miss), and late stent malapposition. Clinical
ollow-up was scheduled at 1, 6, 12, and 13 months (one
onth after clopidogrel withdrawal).
tatistical analysis. Statistical analysis was performed by
he SPSS-PC program. Continuous variables are expressed
s the mean  SD. Categorical variables are expressed as
ercentages. The efficacy and effectiveness of therapy were
ssessed by comparing both primary end points between
roups. Continuous variables were compared by means of
he Student t test. Categorical variables were compared by
eans of the chi-square test or Fisher exact test when at
east 25% of values showed an expected frequency 5. A
wo-tailed value of p  0.05 was considered statistically
ignificant.
ESULTS
aseline and procedural characteristics. Baseline clinical
haracteristics were comparable between groups (Table 1).
arget coronary vessels were well balanced between groups,
s well as the main procedural variables (Table 2). Device
uccess was achieved in 100% of cases.
n-hospital and one-month results. Procedural success
as achieved in 89 (96.7%) of 92 patients. Two patients
llocated to the ICB group presented with a non–Q-wave
able 1. Baseline Clinical Characteristics of Study Population
ICB Group
(n  46)
Control Group
(n  46)
ge (yrs) 66  10 64  10
ales 31 (67%) 32 (69%)
iabetes mellitus 46 (100%) 46 (100%)
Non–insulin-dependent 30 (65%) 30 (65%)
Insulin-dependent 16 (35%) 16 (35%)
obacco use 31 (67%) 33 (71%)
ypertension 25 (54%) 24 (52%)
yperlipidemia 16 (35%) 16 (35%)
revious myocardial
infarction
19 (41%) 21 (46%)
table/unstable angina 24 (52%)/22 (48%) 25 (54%)/21 (46%)
ultivessel disease 24 (52%) 24 (52%)
jection fraction 65  10% 65  13%
ata are presented as the mean value  SD or number (%). p  NS for all variables
continuous variables were compared by means of the Student t test and categorical
ariables by means of the chi-square test).
ICB  intracoronary brachytherapy.I, with raise in CK up to 400 U/l and 900 U/l,espectively. This was related to side-branch occlusion
uring the procedure. Another patient had a noncardiac
eath four days after stenting and brachytherapy due to
emorrhagic shock. None of patients from the nonradiation
rm presented with MACE during hospitalization. No
dditional MACE occurred during the one-month
ollow-up in either group.
esults of IVUS. Quantitative volumetric analysis of the
tented segment is presented in Table 3. At follow-up, the
n-stent luminal volume was significantly larger in the ICB
roup, at the expense of a significant reduction in NIH
olume (Table 3, Fig. 2). The in-stent mean neointimal area
primary end point of efficacy) showed a 55% relative
eduction within irradiated stents (1.04  1.6 mm2 vs. 2.30
1.6 mm2, p  0.0005). In the same way, the percentage
able 2. Baseline Angiographic and Procedural Characteristics
f Study Population
ICB Group
(n  46)
Control Group
(n  46)
reated artery
LAD 19 (41%) 18 (39%)
LCx 13 (28%) 17 (37%)
RCA 14 (30%) 11 (24%)
esion length (mm) 13.0  4.1 11.9  3.2
CC/AHA lesion class B2/C 21 (46%) 23 (50%)
eference diameter (mm) 2.7  0.4 2.7  0.5
LD (mm) 1.0  0.3 1.0  0.3
iameter stenosis (%) 60  9 61  9
tent size (mm) 3.0  0.4 3.0  0.4
tent length (mm) 18.1  6.5 16.1  4.6
alloon-to-artery ratio 1.11  0.14 1.15  0.13
adiation source length
27 mm 33% —
40 mm 52% —
60 mm 15% —
well time (s) 255  123 —
ata are presented as the mean value  SD or number (%). p  NS for all variables
continuous variables were compared by means of the Student t test and categorical
ariables by means of the Fisher exact test for the treated artery and by the chi-square
est for ACC/AHA lesion class B2/C).
ACC/AHA  American College of Cardiology/American Heart Association;
CB intracoronary brachytherapy; LAD left anterior descending coronary artery;
Cx  left circumflex artery; MLD  minimal luminal diameter; RCA  right
oronary artery.
able 3. Quantitative Volumetric Analysis of the Stented
egment by Intravascular Ultrasound
ICB Group Control Group p Value
ost-treatment n  46 n  46
Total vessel volume 326  152 314  121 0.66
Plaque volume 170  76 170  68 0.84
Luminal volume 157  84 146  61 0.45
Stent volume 157  82 146  61 0.45
ollow-up n  42 n  43
Total vessel volume 347  146 312  127 0.24
Plaque volume 203  84 202  86 0.98
Luminal volume 143  80 109  57 0.02
Stent volume 163  83 146  62 0.27
NIH volume 19  29 36  27 0.004
ll volume data are presented as the mean value  SD in mm3 (continuous variables
ere compared by means of the Student t test).ICB  intracoronary brachytherapy; NIH  neointimal hyperplasia.
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Intracoronary Brachytherapy in Diabetic Patients August 4, 2004:520–7f in-stent volume obstruction was significantly lower in the
CB group (13  22% vs. 26  16% in nonradiated group,
 0.002). However, the minimal luminal area of the
ntire segment (primary end point of effectiveness) was
omparable between groups (4.5  2.4 mm2 vs. 4.4  2.1
m2, p  NS) due to a relocation of this cross-sectional
rea to distant segments from the target site in the ICB
roup. By IVUS, one true aneurysm was identified at
ollow-up in an irradiated stent edge inducing proximal late
tent malapposition without clinical consequences.
esults of QCA. The QCA data in the four prespecified
oronary segments are presented in Table 4. Angiographic
arameters were significantly better in the ICB group when
arget and injured segments were analyzed. However, these
ifferences were no longer significant in the entire segment
irradiated plus edges), mimicking the phenomenon evi-
enced by IVUS. Similarly, the restenosis rate progressively
ncreased from the target to entire segments in the irradi-
igure 2. Change in total vessel volume (TVV), plaque volume (PV), and
uminal volume (LV) at the stented segment from post-treatment to
ollow-up between groups. Open bars  control group; shaded bars 
rachytherapy group.
able 4. Quantitative Coronary Angiography of the Four Prespec
Target Segment Injured
ICB Control ICB
efore treatment
MLD 1.0  0.3 1.0  0.3 1.0  0.3
Reference diameter 2.7  0.5 2.7  0.5 2.7  0.5
% Stenosis 60.5  9 61.5  9 60.4  9
Mean diameter 1.9  0.3 1.9  0.3 2.1  0.4
fter treatment
MLD 2.6  0.5 2.5  0.4 2.3  0.5
Reference diameter 2.9  0.5 2.9  0.5 2.9  0.5
% Stenosis 14.4  9.0 14.5  9.0 21  12
Mean diameter 2.9  0.5 2.9  0.4 2.9  0.5
ollow-up
MLD 2.3  0.7 1.8  0.6* 2.1  0.6
Reference diameter 2.8  0.4 2.6  0.6 2.8  0.5
% Stenosis 20  22 35  17† 23  21
Mean diameter 2.6  0.8 2.2  0.6‡ 2.7  0.5
cute gain 1.5  0.5 1.5  0.4 1.3  0.6
ate loss 0.3  0.8 0.8  0.6§ 0.2  0.7
p  0.0001; †p  0.0004; ‡p  0.004; §p  0.005; ¶p  0.006; p  0.008 irrad
ompared by means of the Student t test).Abbreviations as in Table 2.ted group, whereas it remained almost invariable in the
onradiated group (Fig. 3). Cumulative frequency distribu-
ion curves of the MLD demonstrated the discrepancy
etween target and entire segment analyses (Figs. 4 and 5).
he geographic miss phenomenon was detected in four
atients (4.3%). All of them presented with the edge effect
t follow-up.
ix-month and one-year clinical follow-up results. Clinical
ollow-up was performed in 100% of patients at six months
nd one year. Six-month angiographic follow-up was per-
ormed in 91.3% of patients receiving radiation and 93.4%
f patients not receiving radiation. Reasons for missing
ngiographic follow-up included death in two patients (one
ardiac and one noncardiac), MI before follow-up in two
atients, and refusal in the remaining three patients. Over-
ll, there were no statistical differences between groups in
he number of MACE at follow-up (Table 5). However,
hey differ qualitatively between groups. All cases of MACE
n the control group were caused by TVR secondary to
Coronary Segments
ent Irradiated Segment Entire Segment
Control ICB Control ICB Control
.0  0.3 1.0  0.3 — 1.1  0.3 1.1  0.3
.7  0.5 2.7  0.5 — 2.7  0.5 2.7  0.5
.5  9 61  10 — 61  10 61.6  9
.1  0.5 2.3  0.4 — 2.4  0.4 2.3  0.6
.4  0.5 2.1  0.6 — 1.9  0.5 2.0  0.4
.9  0.5 2.9  0.6 — 2.9  0.5 2.9  0.5
7  8 28  13 — 34  11 28  10
.9  0.4 2.9  0.4 — 2.8  0.5 2.8  0.4
.7  0.6‡ 1.9  0.8 — 1.6  0.6 1.6  0.6
.6  0.6 2.8  0.5 — 2.8  0.5 2.6  0.5
5  17¶ 33  22 — 41  11 38  16
.3  0.6‡ 2.6  0.7 — 2.5  0.7 2.5  0.6
.4  0.4 1.0  0.6 — 0.8  0.5 1.0  0.4
.7  0.7 0.2  0.7 — 0.2  0.6 0.5  0.5
vs. control. Data are presented as the mean value  SD (continuous variables were
igure 3. Absolute reduction in restenosis rates in the four prespecified
oronary segments between groups. Open bars  control group; shaded
ars  brachytherapy group.ified
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August 4, 2004:520–7 Intracoronary Brachytherapy in Diabetic Patientsn-stent restenosis. Conversely, MACE in the ICB group
ncluded cardiac death (n  1), MI (n  6), and the edge
ffect (n  6). Also, TVR secondary to restenosis purely
ocated within the stent occurred only in three irradiated
atients (7.1%). The three patients presenting with Q-wave
I showed stent thrombosis related to clopidogrel with-
rawal. Reasons for clopidogrel withdrawal included urgent
astrointestinal surgery in one patient and a referral physi-
ian’s decision in the other two patients. Furthermore, two
on–Q-wave MIs were periprocedural (see earlier text). The
hird one occurred at five months. The patient presented
ith unstable angina and subsequently developed an in-
rease in CK up to 500 U/l. The patient experienced a
evere proximal and distal edge effect not related to geo-
raphic miss. At 13-month follow-up (one month after
lopidogrel withdrawal), there was no additional MACE in
ither group.
linical results according to type of diabetes. The pri-
ary end points derived from IVUS between diabetes types
re presented in Table 6. Overall, no major differences in
esponse to treatment were encountered between insulin-
nd non–insulin-dependent diabetics. On QCA and parallel
o what occurred in the entire population, it appears there
as a treatment effect at the target segment, which faded
igure 4. Cumulative frequency distribution curves of MLD between
roups at the target segment. By comparison, using the Student t test, the
ean MLD at follow-up (F/U) became significant between groups (p 
.0001).
igure 5. Cumulative frequency distribution curves of minimal luminal
iameter between groups at the vessel segment. By comparison, using the
tudent t test, the mean minimal luminal diameter at follow-up (F/U) was
o longer significant between groups.way when the entire vessel segment was analyzed (reste-
osis rates at target, injured, irradiated, and vessel segments
n insulin-dependent diabetics: 20% vs. 0%, 20% vs. 0%,
0% vs. 7.7%, and 26.7% vs. 23.1% [nonradiation vs. ICB
roup], pNS for all comparisons; non–insulin-dependent
iabetics: 21.4% vs. 10.3%, 21.4% vs. 13.8%, 21.4% vs.
7.2%, and 25% vs. 24.1% [nonradiation vs. ICB group], p
NS for all comparisons). Moreover, clinical events were
qually distributed between diabetes type both at six months
nd one year.
ISCUSSION
his is the first randomized trial involving ICB in diabetic
atients with de novo coronary stenoses. This study dem-
nstrated that ICB may be successfully delivered after
tenting and is able to significantly reduce the degree of
n-stent neointimal proliferation at follow-up, as compared
ith conventional stent implantation alone. Thus, the
rimary end point of efficacy, which evaluated the full
herapeutic potential of this technique, showed a significant
eduction of in-stent NIH leading to a restenosis rate of
nly 7% within the target segment. The degree of inhibition
f NIH proliferation observed in our study is comparable to
hat of previous randomized trials of ICB, where relative
able 5. Clinical Follow-Up of Study Population
ICB Group
(n  46)
Control Group
(n  46) p Value
ix-month follow-up
Cardiac death 1 (2.2%) 0 NS
MI 6 (13%) 0 0.02
Q-wave 3 (6.5%)* 0 NS
Non–Q-wave 3 (6.5%) 0 NS
TVR 10 (21.7%)† 11 (23.9%) NS
ne-year follow-up
Cardiac death 1 (2.2%) 0 NS
MI 6 (13%) 0 0.02
Q-wave 3 (6.5%)* 0 NS
Non–Q-wave 3 (6.5%) 0 NS
TVR 10 (21.7%)† 11 (23.9%) NS
otal MACE
(exclusive events)
13 (28.2%) 11 (23.9%) NS
All three Q-wave MIs were secondary to late stent thrombosis. †Six of 10 were due
o the edge effect. Cardiac death and MI variables were compared by means of the
isher exact test and TVR and MACE variables by means of the chi-square test. Data
re presented as the number (%).
ICB intracoronary brachtherapy; MACEmajor adverse cardiac events; MI
yocardial infarction; NS  not significant; TVR  target vessel revascularization.
able 6. Primary End Points According to Diabetes Type
ICB Control p Value
nsulin-dependent n  13 n  15
Mean in-stent NIH 1.1  1.0 1.9  1.2 0.08
MLA in vessel segment 4.5  1.7 4.8  2.2 NS
on–insulin-dependent n  29 n  28
Mean in-stent NIH 1.0  1.8 2.3  1.5 0.005
MLA in vessel segment 4.5  2.7 4.2  2.0 NS
ata are presented as the mean value  SD in mm2 (continuous variables were
ompared by means of the Student t test).MLA  minimal luminal area; other abbreviations as in Table 3.
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5,6). Furthermore, a similar inhibitory effect has been
emonstrated in a recent IVUS substudy from the
AXUS-II trial (25). At six-month follow-up, both the
AXUS-SR (0.7 0.9 mm2) and the TAXUS-MR (0.6
.8 mm2) groups showed a significant reduction in mean
IH, compared with the bare-metal stent (1.9  1.5 mm2,
 0.001).
Besides, our results are concordant to those obtained in
ubanalyses of diabetics treated with ICB from in-stent
estenosis trials (10–12), in which radiation was particularly
eneficial. In a recent subanalysis from the WRIST series
11), diabetics treated with ICB showed a 76% reduction in
inary restenosis rate, compared with placebo, and, as in our
tudy, this benefit applied for both insulin- and non–
nsulin-dependent diabetics. In another substudy from the
amma-1 trial (12), the antirestenosis effect of iridium-192
as larger for diabetic patients than for nondiabetic pa-
ients: the absolute in-lesion restenosis rate was reduced by
0% for diabetics and 16% for nondiabetics.
However, this potent inhibitory effect within the stent
as clinically counteracted by the occurrence of edge reste-
osis and late stent thrombosis. Besides, three events not
elated to the radiation procedure (two non–Q-wave MIs
nd one noncardiac death) occurred in the ICB group.
In this regard, the combination of ICB and stenting of de
ovo coronary stenoses has been discouraging in most
revious trials (13–16). The Dose Finding Study (13)
emonstrated a very low restenosis rate (3.9%) in patients
reated with balloon angioplasty and allocated to the highest
rescribed dose group (18 Gy at a tissue depth of 1 mm).
owever, in this study, those patients receiving a stent had
poor outcome due to high rates of stent occlusion (14.3%)
nd angiographic restenosis (20%). Similarly, in the BRIE
egistry (14), late loss was significantly worse in patients
eceiving a coronary stent with respect to those treated with
onventional balloon angioplasty (0.37 vs. 0.12 mm, p 
.009). The BRIDGE trial (15) randomized 100 patients
ith de novo coronary stenoses to direct stenting or direct
tenting plus ICB. Similar to our results, a significant 50%
eduction in in-stent late loss was observed with ICB, but
his was not accompanied by any clinical benefit due to the
ccurrence of the edge effect and late thrombosis. The
eta-Cath trial (R. E. Kuntz, unpublished data, 2001) also
ailed to demonstrate any clinical benefit of ICB as com-
ared with placebo due to the edge effect. Recently, the
CRIS trial (16) demonstrated that intracoronary beta-
rradiation with a rhenium-188–filled balloon catheter effi-
iently reduced restenosis and revascularization rates in
atients with de novo (71%) and restenotic lesions. Both the
eta-Cath and BRIE trials were designed with the use of
hort radiation sources (30-mm Novoste Beta-rail source),
efore full knowledge of the concept of geographic miss in
nterventional cardiology (19). In contrast, both in the
RIDGE (15) and in the current study, special care inrying to avoid both geographic miss (use of long sources) Ind late thrombosis (prolonged dual-antiplatelet regimen)
as taken. Interestingly, the ECRIS trial did reduce the
ccurrence of the edge effect in de novo stenoses (6%) by
sing an irradiation balloon catheter that exceeded at least 5
m at each side from the traumatized area (16).
The edge effect was involved in six of 10 TVRs in the
CB group and was mostly related to geographic miss.
verall, this phenomenon was confirmed by independent
nalysis in four patients (4.3%), but all of them eventually
resented with a clinically relevant edge effect. Geographic
iss, however, was not demonstrated in the other two
atients with the edge effect in whom long enough sources
ere used to cover the entire injured segment plus margins.
n such patients, injury at a distance not evident on
ngiography or a source-induced injury cannot be ruled out.
In our trial, 6.5% of ICB patients presented with late
tent thrombosis, as compared with 0% in the control arm.
his increased rate of thrombosis mimics that of historical
eries (20,26), although it is clearly higher than that found
n recent studies employing a long-term, dual-antiplatelet
egimen (aspirin and thienopyridines) (16,27). In our study,
ate thromboses were associated in all cases with clopidogrel
ithdrawal as these occurred five and seven days after drug
ithdrawal. The rate of compliance with the dual-
ntiplatelet regimen in our trial was 93.4%, which was high
bove that of other trials designed to evaluate the efficacy of
ong-term use of clopidogrel (28,29). In particular, in the
REDO trial (28) and CURE trial (29), 63% and 78.9% of
atients enrolled completed the full one-year course of the
tudy drug, respectively. On the other hand, none of the
emaining patients presented with stent thrombosis after
lopidogrel withdrawal at 12 months.
This experience has shed light on the potential and
imitations of this technique and may represent a rationale
or the correct use of new antirestenotic devices, such as
rug eluting stents, which also exhibit a potent in-stent
ntiproliferative effect.
tudy limitations. This is a single-center trial with a small
ize population. Although this study is well powered for the
rimary end point derived from IVUS, the relatively small
ize impedes one from drawing any definitive conclusion
bout the clinical data, as the study was not powered to
etect clinical differences between the two groups.
In order to assess the effectiveness of the technique, this
rial is not blinded (no sham source was introduced in
ontrol subjects). However, the measure of the primary end
oints by IVUS analysts, who were blinded to the treatment
llocation, makes the study well validated for both the
fficacy and effectiveness evaluation. For obvious reasons,
CA analysis was not blinded. However, these secondary
nd points derived from QCA corroborated the results of
he primary end points derived from a blinded IVUS
valuation.
Finally, this trial evaluated a cohort of diabetic patients
menable to being treated with conventional stenting,
VUS, and ICB. Thus, these results cannot be extrapolated
t
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oronary stenoses not suitable for stenting, IVUS analysis,
r ICB with current sources. As a matter of fact, this cohort
f patients represents 25% of diabetic patients treated with
ngioplasty in our institution during the recruitment period.
eprint requests and correspondence: Dr. Manel Sabate´, Servicio
e Cardiologı´a, Hospital Clı´nico San Carlos, Plaza Cristo Rey s/n,
8040 Madrid, Spain. E-mail: msabate.hcsc@salud.madrid.org.
EFERENCES
1. The BARI Investigators. Influences of diabetes on 5-year mortality
and morbidity in a randomized trial comparing CABG and PTCA in
patients with multivessel disease. Circulation 1997;96:1761–9.
2. Kip KE, Faxon DP, Detre KM, et al., for the Investigators of the
NHLBI PTCA Registry. Coronary angioplasty in diabetic patients:
the National Heart, Lung, and Blood Institute Percutaneous
Transluminal Coronary Angioplasty Registry. Circulation 1996;94:
1818 –25.
3. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes
mellitus on early and late outcome after percutaneous transluminal
coronary angioplasty. Circulation 1995;91:979–89.
4. Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical
and angiographic outcome after coronary stent placement. J Am Coll
Cardiol 1998;32:1866–73.
5. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to
inhibit restenosis after coronary stenting. N Engl J Med 1997;336:
1697–703.
6. Waksman R, White LR, Chan RC, et al. Intracoronary -radiation
therapy after angioplasty inhibits recurrence in patients with in-stent
restenosis. Circulation 2000;101:2165–71.
7. Leon MB, Moses JW, Lansky AJ, et al. Catheter-based gamma
radiation to inhibit in-stent restenosis. N Engl J Med 2001;344:
250–6.
8. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of
90Sr/90Y beta-radiation versus placebo control for treatment of in-stent
restenosis. Circulation 2002;106:1090–6.
9. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of
localised intracoronary beta radiation in treatment of in-stent resteno-
sis: the INHIBIT randomised controlled trial. Lancet 2002;359:
551–7.
0. Teirstein PS, Massullo V, Jani S, et al. A subgroup analysis of the
Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial.
Int J Radiat Oncol Biol Phys 1998;42:1097–104.
1. Gruberg L, Waksman R, Ajani AE, et al. The effect of intracoronary
radiation for the treatment of recurrent in-stent restenosis in patients
with diabetes mellitus. J Am Coll Cardiol 2002;39:1930–6.
2. Moses JW, Moussa I, Leon MB, et al. Effect of catheter-based
iridium-192 gamma brachytherapy on the added risk of restenosis
from diabetes mellitus after intervention for in-stent restenosis (suba-
nalysis of the GAMMA I randomized trial). Am J Cardiol 2002;90:
243–7.
3. Verin V, Popowski Y, de Bruyne B, et al. Endoluminal beta-radiation
therapy for the prevention of coronary restenosis after balloon angio-
plasty. N Engl J Med 2001;344:243–9.4. Serruys PW, Sianos G, van der Giessen W, et al. Intracoronary
beta-radiation to reduce restenosis after balloon angioplasty and
stenting: the Beta Radiation In Europe study. Eur Heart J 2002;23:
1351–9.
5. Serruys PW, Wijns WJ, de Scheerder I, et al. Primary results of the
BRIDGE (Beta Radiation Investigation with Direct stenting and
Galileo in Europe) trial (abstr). Circulation 2002;106 Suppl II:II621.
6. Ho¨her M, Wo¨hrle J, Wohlfrom M, et al. Intracoronary beta-
irradiation with a rhenium-188–filled balloon catheter: a randomized
trial in patients with de novo and restenotic lesions. Circulation
2003;107:3022–7.
7. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Defi-
nition, diagnosis and classification of diabetes mellitus and its
complications. Part 1: Diagnosis and classification of diabetes
mellitus. Provisional report of a WHO consultation. Diabet Med
1998;15:539 –53.
8. Raizner AE, Cafee RV. The Guidant intravascular brachytherapy
system. In: Waksman R, Serruys PW, editors. Handbook of Vascular
Brachytherapy. London: Martin Dunitz Ltd., 1998:53–8.
9. Sabate´ M, Costa M, Kozuma K, et al. Geographic miss: a cause of
treatment failure in radio-oncology applied to intracoronary radiation
therapy. Circulation 2000;101:2467–71.
0. Costa MA, Sabate´ M, van der Giessen WJ, et al. Late coronary
occlusion after intracoronary brachytherapy. Circulation 1999;100:
789–92.
1. von Birgelen C, Di Mario C, Li W, et al. Morphometric analysis in
3-dimensional intracoronary ultrasound: an in vivo and in vitro study
performed with a novel system for the contour detection of lumen and
plaque. Am Heart J 1996;132:516–27.
2. von Birgelen C, de Vrey EA, Mintz GS, et al. ECG-gated
3-dimensional intravascular ultrasound: feasibility and reproducibility
of the automated analysis of coronary lumen and atherosclerotic plaque
dimensions in humans. Circulation 1997;96:2944–52.
3. Sabate´ M, Serruys PW, van der Giessen WJ, et al. Geomeric vascular
remodeling after balloon angioplasty and beta-radiation therapy: a
three-dimensional intravascular ultrasound study. Circulation 1999;
100:1182–8.
4. Sabate´ M, Costa MA, Kozuma K, et al. Methodological and clinical
implications of the relocation of the minimal luminal diameter after
intracoronary radiation therapy. J Am Coll Cardiol 2000;36:1536–41.
5. Tanabe K, Serruys PW, Degertekin M, et al. Chronic arterial
responses to polymer-controlled paclitaxel-eluting stents: comparison
with bare metal stents by serial intravascular ultrasound analyses. Data
from the randomized TAXUS-II trial. Circulation 2004;109:196–200.
6. Waksman R, Bhargava B, Mintz GS, et al. Late total occlusion after
intracoronary brachytherapy for patients with in-stent restenosis. J Am
Coll Cardiol 2000;36:65–8.
7. Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six-months of
clopidogrel to reduce major cardiac events in patients undergoing
gamma-radiation therapy for in-stent restenosis: Washington Radia-
tion for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
Circulation 2002;106:776–8.
8. Steinhubl SR, Berger PB, Tift Mann J III, et al. Early and sustained
dual antiplatelet therapy following percutaneous coronary intervention:
a randomized controlled trial. JAMA 2002;288:2411–20.
9. The Clopidogrel in Unstable Angina to Prevent Recurrent Events
Trial Investigators. Effects of clopidogrel in addition to aspirin in
patients with acute coronary syndromes without ST-segment eleva-
tion. N Engl J Med 2001;345:494–502.
